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A B S T R A C T
The Department of Haematology/Oncology at the University Children’s Hospital Bern (HONK), has adopted an
integrative approach in addition to state of the art oncological care and implemented a collaboration with the
Institute of Complementary Medicine IKOM, University of Bern, over the past 10 years. Stakeholder satisfaction
with this service was high. We present descriptive data and report on 4 exemplary patients treated with addi-
tional individualized homeopathy (iHOM). Data concerning frequency of consultations, pathologies, follow-ups
and clinical results were reviewed and summarized using descriptive statistics.
94 paediatric oncologic patients consulted for iHOM. Indications for the complementary treatment was wide-
ranging. No interactions with conventional treatment and no adverse side-eﬀects of iHOM were detected. We
present four characteristic patient histories, in which iHOM was used in addition to standard treatment for
mucositis, permissive tissue infection, insomnia and aﬀective dysfunctions. All four patients clinically improved
in an immediate temporal relationship to the additional treatment.
Conclusion: The collaboration between HONK and IKOM established iHOM in paediatric oncology in Bern. In
this setting, iHOM was a safe and supportive additional treatment for various indications during the conven-
tional cancer care. However, no generalizable results can be deducted from these data. We emphasize future
research on this topic.
1. Introduction
Complementary and alternative therapies (CAM) 1 are frequently
used in the treatment of acute and chronic diseases and the acceptance
is high 1,2,3 especially in paediatric 4,5 and cancer patients.6 CAM usage
seems to be higher during the palliative phase of the conventional
treatment with homeopathy as the most often used CAM method
(32%).7 A pilot survey among 1063 families, registered in the paediatric
cancer statistics, stated that 35% of them used CAM during the course
of their child’s disease.8 Again, the most frequent method used was
homeopathy with 45.2%. These results coincide with our observations
at HONK with use of individualized homeopathy or homeopathic re-
medies by 43% of CAM users.4 It seems therefore justiﬁed to take a
closer look at the spectrum of speciﬁc homeopathic interventions in this
ﬁeld. In this article, the scope of the collaboration between the Institute
of Complementary Medicine IKOM (department for homeopathy) at the
University of Bern and the department for haematology and oncology at
the Paediatric University Hospital in Bern (HONK), is outlined as an
exemplary concept of integrative medicine (IM) by deﬁnition of the
Consortium of Academic Health Centers for Integrative Oncology.9
Thus, the aim of the study was to present descriptive data of this col-
laboration along with four detailed case histories.
2. Methods
The specialist doctors from the department for homeopathy at IKOM
practice individualised homeopathy (iHOM), a term which refers to
individually administered homeopathic prescriptions of a single re-
medy, selected after a process of matching the present symptoms of the
patient with those described in the homeopathic medicines’ textbook
https://doi.org/10.1016/j.ctim.2018.10.010
Received 7 June 2018; Received in revised form 12 October 2018; Accepted 15 October 2018
Abbreviations: ALL, acute lymphoblastic leukaemia; CAM, complementary and alternative medicine or therapies; CML, chronic myeloid leukaemia; CTX, che-
motherapy; HONK, Department of Haematology/Oncology at the University Children’s Hospital Bern; iHOM, individualized homeopathy; IKOM, Institute of
Complementary Medicine at the University of Bern; IM, integrative medicine
⁎ Corresponding author.
E-mail addresses: katharina.gaertner@ikom.unibe.ch (K. Gaertner), Sonja.Lueer@insel.ch (S.C. Lüer), martin.frei@ikom.unibe.ch (M. Frei-Erb),
klaus.vonammon@ikom.unibe.ch (K. von Ammon).
Complementary Therapies in Medicine 41 (2018) 267–270
Available online 16 October 2018
0965-2299/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
“Materia Medica” following the „Law of Similars”.10 From June 2007
until present IKOM provides consultations at HONK on request of pa-
tients. For the treatment, only highly diluted and succussed, i.e. so-
called potentized homeopathic remedies, where we suspect no mole-
cular interaction with conventional therapies, were used. In particular,
‘C-Potencies’, in which the original substance is diluted 1:100, followed
by 10 succussions and ‘Q-Potencies’, in which the original substance is
diluted 1:50′000, followed by 2–10 succussions are prescribed. The
number of the potency (e.g. 30, 200 or 3, 5 respectively) indicates the
number of repetitions of this process. Two pharmacies, either Spagyros®
11 or Schmidt-Nagel®,12 approved by the Swiss Agency for Therapeutic
Products (Swissmedic), provided the homeopathic remedies. They were
prepared following the instruction of the European Pharmacopoeia,
Monograph 1038 12 and 2045 11 and the Homeopathic Pharmacopoeia
(HAB 5.2.2–5.2.6).
Jurisdiction of the Ethics Committee of the Canton Bern was ob-
tained. Thereafter, documentation of case histories at IKOM were re-
viewed and diagnoses, dates of diagnoses and treatments were ex-
tracted to Excel-ﬁles. Descriptive statistics were used to describe the
frequency of consultations and pathologies. Medians and ranges as well
as means and standard deviation (SD) are shown. Exemplary patients
were chosen and informed consent of the respective patients and their
families was obtained by postal contact. The case histories consist of
characteristic indications for iHOM-consultations, a description of the
homeopathic approach and the subjectively reported results.
3. Results
From June 2007 until December 2017, ninety-four paediatric on-
cologic patients at HONK had at least 1 homeopathic consultation. The
diagnoses of the complementarily treated patients comprised mostly
hematologic neoplasia (n=40; 42.6%) and brain tumours (n=28;
29.8%). Average time from diagnosis to homeopathic consultation was
2.4 months (SD 4.9), with a range from 1 to 38 months. The ﬁrst
consultation of the patients and their families with the IKOM-doctors
mostly consisted of an informative meeting with or without a homeo-
pathic anamnesis and concerned various indications for complementary
homeopathic therapy. All patients except three received supportive
homeopathic care. Homeopathic treatment started during conventional
in-patient treatment and was continued in the iHOM ambulatory if
necessary.
The frequency of consultations per patient was 9.6 at the mean,
ranging from 1 to 67 iHOM sessions. The median was 8 consultations.
Core areas of the iHOM-interventions were the treatment of side-eﬀects
from chemo- or radiotherapy and other acute events during the course
of the disease. This comprised mucositis, habitual infections, neuro-
psychologic and psycho-vegetative changes in the child. These events
were treated considering the observed signs and symptoms of the acute
episode for the prescription of the homeopathic remedy. C-Potencies in
the 30th up to the 10′000th dilution, with repeated dosing if needed,
were used. If no acute problems were evident or the patient complaint
about a general aggravation of chronic symptoms, the patients received
a remedy, which corresponded to their chronic condition, i.e. a so-
called constitutional remedy, either as C-potencies or Q-Potencies. The
evolution of the patients after iHOM treatment varied for each in-
dividual subject and condition, for which iHOMwas used. Therefore, no
overall results can be presented. Instead, 4 case-summaries are desig-
nated to illustrate the variety and possibilities of iHOM at HONK.
4. Case summaries
4.1. Case 1 - mucositis
This female patient was diagnosed with Acute Lymphoblastic
Leukaemia (ALL) at nearly 5 years of age (4 10/12). Two weeks after
diagnosis, the family asked for complementary homeopathic treatment.
In the anamnesis digestive problems appeared to be the most trouble-
some complaint for the patient. She suﬀered from constipation and
abdominal cramps. Silicea C30 11 (size 2), 1× 5 globules per day, was
prescribed upon basis of totality of symptoms. On the follow-up con-
sultation two weeks later, her mother reported that the abdominal
cramps had stopped and her appetite had improved. The therapy was
paused. Two weeks later, during the next cycle of chemotherapy (CTX)
the girl developed mucositis and for pain-control she needed opiates
intravenously. She had been on anti-mycotic therapy for four days,
before she was seen by an iHOM-doctor again. The mucosa of the
mouth was thickly coated with thrush; the patient received sedative
drugs but presented restless extremities and salivation. Mercurius so-
lubilis C200,11 1×5 globules (size 2) per day was given. On iHOM-
ward round the next day, the girl was sitting at the table playing puz-
zles. The mother reported, that after the intake of the globules last
evening, there had been an episode of diarrhoea with a large amount of
stool and the patient was sleeping afterwards. Opiates had been re-
duced already and this morning she asked for food for the ﬁrst time
since the start of mucositis. The family was told to continue the ho-
meopathic treatment until complete disappearance of mucositis symp-
toms. In the next homeopathic control ﬁve days later, she had no pre-
sent complaints and the remedy was stopped.
4.2. Case 2 – tissue infection during neutropenia
A 22-month old girl, diagnosed with Early T-cell Precursor ALL,
high-risk group,13 was presented to IKOM for general advice. She was
presenting no acute symptoms but the parents of the child stated the
wish to support their child’s immune system. Based on her general
symptoms, she was given Phosphorus C200 11 without any noticeable
eﬀect. Moreover, she has been admitted to hospital with fever and an
acute tissue infection of the left cheek two weeks later. Swelling and
reddening were discrete, but there was complete loss of appetite and
demonstration of pain, whenever touched or moved. In order to with-
stand pain during examinations she needed opiates. Corresponding
homeopathic evaluation, Bryonia C200,12 up to 3×5 globules (size 10)
per day, was prescribed. The treatment started in the evening and until
noon the other day, the girl seemed to have no pains and tried some
food in the morning. The homeopathic remedy was repeated in the
afternoon, as the pains returned. Within the next days, the time after
which Bryonia needed to be repeated became shorter and on the fourth
day the potency was risen to Bryonia C1000 12 in the same dosing.
While the infection persisted despite the administration of antibiotic
and anti-mycotic therapy, it was neither spreading nor did the girl
seemed to have pain. Every time she expressed discomfort, Bryonia
seemed to help her. Eventually the eﬀect of Bryonia C1000 subsided as
well and the potency was risen to Bryonia C10′000,12 again in the same
dosing. On day six, the antibiotic treatment was adapted. Within the
following two days, the infection reduced further. Nonetheless, a few
days later control imaging revealed remains of the infections needed
and the area to be drained surgically.
4.3. Case 3 – sleeping disorder
A nearly 16-years (15 10/12) old female patient with Chronic
Myeloid Leukaemia (CML) was referred to IKOM with sleeping pro-
blems. The CML was diagnosed 7 weeks prior to the consultation and
the patient reported, that she wasn’t able to sleep without benzodia-
zepines due to too many thoughts. This condition had started with the
CTX. Beforehand, she had already noted nervous anxiety along with
attacks of vertigo and diarrhoea in the morning before presentations at
school or other important events. Further, she suﬀered from frequent
headaches. Those symptoms had also aggravated since CTX. She said,
apart from the bad sleep, there weren’t any new symptoms, only her
general condition had deteriorated. The homeopathic analysis lead to
the prescription of Natrum muriaticum, which she was given in the
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potency Q3 11 (10ml ﬂasks), 3 drops in 10ml tap water per day. After
two month she contacted the doctors at IKOM again and reported that
she had been sleeping very well and had less headaches. When the ﬂask
had been empty after six weeks, however, the sleeping problems re-
turned. She was prescribed Natrum muriaticum Q6 11 in the same
dosing and the sleep became sound again. She was told to consult the
homeopathic doctor if needed. Up to today there was no further con-
tact.
4.4. Case 4 – aﬀect spasm
iHOM doctors were contacted concerning a 16-month old boy, who
had been diagnosed with Acute Myeloid Leukaemia, Fab type M7, 4
days prior to the ﬁrst homeopathic consultation, because his mother
wanted to support the course of disease with iHOM. The anamnesis
revealed that the boy, apart from being weak since the start of CTX, was
stubborn, dissatisﬁed and crying a lot. He was not compliant during
examinations and therapeutic interventions, such as injections or
mouth hygiene, screaming and presenting a spastic arrest of breathing.
Thus, the interventions took a lot of time and sometimes even needed to
be postponed. The boy would only calm himself, when carried and
rocked by his mother. The treatment in this case was Chamomilla C200
11 (size 2), 1× 3 globules sublingual once. In the control visit a week
later, the mother reported that there haven’t been any aﬀect spasms
since the intake of the remedy and the boy was more content and
amenable. She was told, that the homeopathic Chamomilla could be
repeated, whenever the spasm returned. If a repetition had not the
desired result, iHOM should be contacted again. No more contact was
needed.
5. Discussion
IHOM at HONK is used for a broad spectrum of indications during
the course of cancer treatment and the oﬀer is taken by around a
quarter of the concerned families.4 This article presents some of the
diﬀerent indications in which the complementary homeopathic treat-
ment was used over ten years and 4 cases in particular. This insight
might create awareness for the scope of such treatment, as patients and
their families reported an additional beneﬁt to conventional care con-
sistently. The four cases represent iHOM as a regulatory therapy: in case
1, the turning point for the physiological functioning of the mucous
membranes seems to have occurred after the intake of the homeopathic
medicine. In case 2 the homeopathic remedy seemed to work as a
palliative for pain. Cases 3 and 4 represent an aggravation of chronic
symptoms during hospitalisation and chemotherapy respectively. Here,
the administered iHOM seemed to have helped the psycho-vegetative
regulation. This suggested regulatory eﬀect of iHOM in cancer care is
also supported by two controlled pilot studies on iHOM in cancer pa-
tients: Rostock et al. found in a prospective observational study with
two independent cohorts an improvement of quality of life in patients
treated complementary with homeopathy.14 Further, the homeopathic
cohort showed a tendency in decreasing fatigue. In a pragmatic ran-
domized controlled trial Frass et al. found a signiﬁcant stronger im-
provement of global health status and subjective wellbeing in patients
treated additionally with homeopathy than in the control group with
only conventional therapy.15 Laboratory experiments evaluating the
eﬀect of potentised substances show an immune-modulatory response
of cancer cells to homeopathic remedies.16,17
An additional advantage of the complementary treatment with
iHOM, especially in paediatrics, was the safety of this therapy: during
the 10 years of collaboration at our institution no severe side-eﬀects or
drug-interactions with conventional therapy were observed. We share
this experience with another centre, which integrated homeopathy in
the care of critically ill paediatric patients.18 Positive eﬀects of ho-
meopathic treatment in pediatric out-patient care were found for dif-
ferent diseases e.g. acute diarrhoea,19 acute otitis media 20,21 and
attention deﬁcit (hyperactivity) syndrome (ADHS).22 These aspects
were also conﬁrmed by data from a multicentric cohort study on long-
term results of iHOM in chronic diseases with 3709 patients including
819 children.23 Severity of complaints improved signiﬁcantly between
baseline and two years follow up. This improvement persisted until the
follow-up after eight years.24 The biggest limitation of our study,
however, is the lack of a control group or long-term results. That way,
no generalizable results can be deducted from these data. With regard
to patients’ needs for integrative methods, their high acceptance 4,6,7
and the above mentioned empiric literature, upcoming large-scale
clinical studies, including controls, quantitative evaluations and mixed
methods approaches, are warranted.
6. Conclusion
The collaboration between HONK and IKOM established iHOM as a
part of their IM-concept in paediatric oncology in Bern. In this setting,
iHOM seems to be a safe supportive method in cancer treatment of
children and may have contributed to symptom control. Yet, no gen-
eralizable results can be deducted from these data. Future research on
this topic using a mixed methods approach is warranted therefore.
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